News Focus
News Focus
icon url

XenaLives

09/18/18 9:46 AM

#165845 RE: Doc328 #165842

As a patient with CNS issues...

I find that doctors are not fully aware of the side effects a patient sufferes.

Patients are not often aware that what they are suffering from is the medication not the medical issue.

Both doctors and patients need to pay attention to toxicity in all drugs, but especially CNS drugs.

I have TBI from chronic hypoxia. I recently tapered off of Alprazolam on my own. The only CNS drug I use is Primidone in the evening, this is to treat the tremor that is a side effect of Buspirone.

It is fact that the "rare" side effects cited by my doctors are probably not nearly as rare as they think they are, there is no reliable post approval study to track side effects. It would be much better to abandon the P-1-2-3 system and go to a graduated system with more money being spent on P4 studies of long term toxicity and incidence of side effects in larger populations.

Anavex is moving the science of drug study in this direction. 21st Century medicine in more ways than one.

The reading that I have done in the course of DD on AVXL and the posts of others on this board have been extremely informative, a big thank you to those who continue to post on the science.


icon url

ExtremelyBullishZig

09/18/18 11:41 AM

#165861 RE: Doc328 #165842

The problem I have is that your logic for needing another 3 doesn't make sense. It is a 2B / 3 for a reason. It count as a 3. Or else it would just be a 2b. if the governing body agree to a 2B / 3... They are saying that the 3 portion counts as a 3 if the primary endpoint is met. There really isn't anything up for debate at that point.